| Literature DB >> 21151732 |
Abstract
This article reviews the literature on management of chronic cyclical pelvic pain (CCPP). Electronic resources including Medline, PubMed, CINAHL, The Cochrane Library, Current Contents, and EMBASE were searched using MeSH terms including all subheadings and keywords: "cyclical pelvic pain", "chronic pain", "dysmenorrheal", "nonmenstrual pelvic pain", and "endometriosis". There is a dearth of high-quality evidence for this common problem. Chronic pelvic pain affects 4%-25% of women of reproductive age. Dysmenorrhea of varying degree affects 60% of women. Endometriosis is the commonest pathologic cause of CCPP. Other gynecological causes are adenomyosis, uterine fibroids, and pelvic floor myalgia, although other systems disease such as irritable bowel syndrome or interstitial cystitis may be responsible. Management options range from simple to invasive, where simple medical treatment such as the combined oral contraceptive pill may be used as a first-line treatment prior to invasive management. This review outlines an approach to patients with CCPP through history, physical examination, and investigation to identify the cause(s) of the pain and its optimal management.Entities:
Keywords: chronic pain; cyclical pelvic pain; dysmenorrhea; endometriosis; nonmenstrual pelvic pain
Year: 2010 PMID: 21151732 PMCID: PMC2990894 DOI: 10.2147/IJWH.S7991
Source DB: PubMed Journal: Int J Womens Health ISSN: 1179-1411
Etiologies of chronic pelvic pain
| Gynecological | Physiologic |
| Primary dysmenorrhea | |
| Mittelschmerz | |
| Pathologic | |
| Endometriosis | |
| Adenomyosis | |
| Fibroid (uterine leiomyoma) | |
| Cervical stenosis or obstructive abnormality | |
| Pelvic venous congestion syndrome | |
| Ovarian remnant/residual ovary syndrome | |
| Pelvic adhesions | |
| Postpelvic inflammatory disease | |
| Endosalpingiosis | |
| Gastrointestinal tract | Irritable bowel syndrome |
| Inflammatory bowel disease | |
| Chronic constipation | |
| Urinary tract | Interstitial cystitis |
| Nervous system | Pudendal neuralgia |
| Provoked vestibulodynia | |
| Muscloskeletal | Pelvic floor myalgia |
| Myofascial pain | |
| Psychosocial | Depression |
| Physical/sexual abuse | |
| Drug seeking behavior |
Note: May cause cyclic pelvic pain in relation to menstrual cycle.
Randomized controlled trials comparing therapeutic options for CCPP
| RCT | Intervention | Result and efficacy | Side effects | |
|---|---|---|---|---|
| Chronic pelvic pain with endometriosis | ||||
| COCP | Vercellini et al | Goserelin depot vs low-dose | Both groups had significantly reduced deep dyspareunia (goserelin superior with mean difference of 1.8; 95% CI, 0.1–3.5) and nonmenstrual pain (no difference) | Migraine |
| Harada et al | Monophasic COCP vs placebo for 4 months | COCP group had significantly reduced verbal rating score for dysmenorrhea and volume of endometrioma on ultrasonography | ||
| GnRHa | Rock et al | Zoladex (goserelin acetate implant) vs danazol for 6 months | Zoladex is as effective as danazol in the treatment of endometriosis, 53% reduction in AFS endometriosis score with Zoladex vs 46% with danazol | Hypoestrogenism (Vasomotor symptoms, reduction in bone mineral density and osteoporosis) |
| Gregoriou et al | GnRHa alone vs GnRHa plus HRT for 6 months | Both groups equally effective in reducing pelvic pain with no difference of reduction of CPP in both group ( | ||
| LNG-IS | Petta et al | LNG-IS vs GnRHa for 6 months | LNG-IS is as effective as GnRHa in treatment of endometriosis-associated CPP with no difference of reduction of CPP in both group ( | Spotting |
| Progestagens | Vercellini et al | Depot medroxy progesterone acetate (MDA) vs OCOP + Danazol for 12 months | MDA group had reduced dysmenorrhea (mean difference VAS score 2.1; 95% CI, 0.8–3.4). | Amenorrhea |
| Surgery | Sutton et al | Laser ablation of endometriosis plus | 62.5% of laser ablation and LUNA had improved pain VAS scores and 22.6% in expectant group at 6 months ( | No operative or laser complications |
| Abbott et al | Full excision of endometriosis vs diagnostic laparoscopy | Pain improved in 80% with immediate full excision vs 32% in diagnostic laparoscopy ( | No difference in surgical morbidity in both groups | |
| Wright et al | Excision vs ablation of endometriosis in mild endometriosis (rAFS classification 1-2) | Both excision and ablation reduced pain scores and pelvic tenderness | No difference in surgical morbidity in both groups | |
| Jarell et al | Excision of endometriosis vs expectant management | Pain was significantly reduced at 1 year ( | No difference in surgical morbidity in both groups | |
| Chronic pelvic pain alone | ||||
| COCP | No RCT | |||
| LNG-IS | No RCT | |||
| GnRHa | Ling | Depot Leuprolide vs placebo for 3 months | Depot Leuprolide group had reduced dysmenorrhea (pain score 1.0 vs 2.7, | Hypoestrogenism (Vasomotor symptoms, reduction in bone mineral density) |
| Pudendal nerve block | No RCT | |||
| Botulinum toxin type A | Abbott et al | Bolulinum toxin type A vs placebo in patients with CPP and pelvic floor muscle spasm | Botulinum toxin A group had reduced dyspareunia (VAS score 66 vs 12, | Cost |
| Adhesiolysis | Keltz et al | Right paracolic adhesiolysis vs no lysis | Patients undergone right paracolic adhesiolysis had greater pain reduction than those who did not ( | No difference in surgical morbidity in both groups |
Abbreviations: COCP, combined oral contraceptive pill; CI, confidence interval; GnRHa, gonadotrophin-releasing hormone analog; LNG-IS, levonorgestrel-releasing intrauterine system; CPP, cyclical pelvic pain; LUNA, laparoscopic uterine nerve ablation. RCT, randomized controlled trials; HRT, hormone replacement therapy; VAS, visual analog scale; AFS, American Fertility Society.
Figure 1Flowchart describing a proposed management of chronic cyclic pelvic pain.